The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.b

Antiphospholipid antibodies w/wo the APL syndrome

Publications

Kolarz B, Majdan M, Darmochwal-Kolarz DA, Dryglewska M

Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.

Medical science monitor : international medical journal of experimental and clinical research. 2014;20:1227-31

Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Bérard F

Arterial thrombosis with anti-phospholipid antibodies induced by infliximab.

European journal of dermatology : EJD. 2007;17(6):546-7

Eklund KK, Peltomaa R, Leirisalo-Repo M

Occurrence of pulmonary thromboembolism during infliximab therapy.

Clinical and experimental rheumatology. 2003;21(5):679